As another Alzheimer’s treatment fails, experts are divided on where to next
In a development that researches have called ‘crushing’, two new Alzheimer’s drug treatments have failed their latest clinical trial. This latest failure, added to the 300 drugs that have already been found ineffective for treatment of Alzheimer’s, have led some experts to question the direction of research.
The two treatments, solanezumab and gantenerumab, are both anti-amyloids, as were the majority of treatments in the last 30 years. The near-comprehensive failure of anti-amyloids to date have led some researchers to question whether the accumulation of amyloid plaques in the brain are a cause or marker of Alzheimer’s.
The DIAN-TU trial of the drugs attempted to mitigate the perceived flaws of previous studies by using a much higher dosage and recruiting healthy individuals with a genetic certainty of developing Alzheimer’s and extending the duration to five years.
While no researchers a yet willing to completely rule out the amyloid theory, some – such as UTS director of neuroscience ...